Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Are: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Inflammatory Mediators | regulates | process | 0.80 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 14 hypotheses Top: 0.791
neurodegeneration | 2026-04-01 | 12 hypotheses Top: 0.777
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Longitudinal dietary change analysis and ADRD risk over 10 years | clinical | Alzheimer's disease and relate | 0.930 | 0.00 | human patients | proposed | N/A |
| Irisin effects on angiogenesis in human endothelial cells | exploratory | bone fracture | 0.900 | 0.00 | human umbilical vein endotheli | proposed | N/A |
| Proposed experiment from debate on Senolytics targeting p16/p21+ senes | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| cGAS-STING Pathway Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Microglial Aging and Immune Memory in Neurodegeneration — Training the | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Microglial Contributions to Huntington's Disease Pathogenesis | validation | Neuroinflammation | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Mixed Pathology Effects on Parkinson's Disease Progression and Treatme | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NLRP3 Inflammasome Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Traumatic Brain Injury and Alzheimer's Disease Relationship | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Cytochrome Therapeutics | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Peroxisomal Dysfunction Validation in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Prodromal Parkinson's Disease Biomarker Development — Early Detection | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Caloric Restriction Intervention Alters Specific Circulating Biomarkers of the S [PMID:37738560] | Justice JN, Leng XI, LeBrasseur NK, Tchk | J Gerontol A Biol Sci Med Sci | 2024 | 1 |
| Increased mitophagy protects cochlear hair cells from aminoglycoside-induced dam [PMID:35471096] | Zhang Y, Fang Q, Wang H, Qi J, Sun S, Li | Autophagy | 2023 | 1 |
| Sex differences in autophagy-mediated diseases: toward precision medicine. [PMID:32264724] | Shang D, Wang L, Klionsky DJ, Cheng H, Z | Autophagy | 2021 | 1 |
| Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populatio [PMID:33144684] | He D, Wang D, Lu P, Yang N, Xue Z, Zhu X | Oncogene | 2021 | 1 |
| BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains. [PMID:32722981] | Wu X, Zheng Y, Liu M, Li Y, Ma S, Tang W | Autophagy | 2021 | 1 |
| Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells [PMID:26657143] | Chang J, Wang Y, Shao L, Laberge RM, Dem | Nat Med | 2016 | 1 |
| The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. [PMID:25754370] | Zhu Y, Tchkonia T, Pirtskhalava T, Gower | Aging Cell | 2015 | 1 |
| SIRT5 regulation of ammonia-induced autophagy and mitophagy. [PMID:25700560] | Polletta L, Vernucci E, Carnevale I, Arc | Autophagy | 2015 | 1 |
| PRKAB2 as a tumor suppressor in renal cell carcinoma: inhibiting mitophagy via t [PMID:41612594] | Chen K, Zhang Y, Ruan H, Wei Z, Wang K, | Autophagy | 2026 | 0 |
| Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990] | Keller A | Annual review of physiology | 2026 | 0 |
| ROS-responsive nanogels for brain targeted delivery of icariin in the treatment [PMID:41197818] | ["Li X", "Huang J", "Zhou Y", "Chen X", | International journal of pharm | 2026 | 0 |
| Single-Cell RNA Sequencing and Network Pharmacology Reveal the Potential Role of [PMID:41610872] | ["Niu J", "Wang L", "Qi J", "Lu G"] | The journal of gene medicine | 2026 | 0 |
| Integrated Profiling of DEHP-Induced Hippocampal Neurotoxicity in Adult Female R [PMID:41600627] | Bai J, Li J, Tang L, Sun W, Gao F, Zhang | Toxics | 2026 | 0 |
| Senolytic elimination of therapy-induced senescent cells by ABT-263 improves che [PMID:41423036] | Zhang D, Zhu J, Zou R, Zhang H, Yu BP, L | Biochemical pharmacology | 2026 | 0 |
| Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811] | Wang Y, Zhang Z, Cao L, Huang S, Huang X | J Ethnopharmacol | 2026 | 0 |
| Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710] | Yang X, Xiao JH, Li X, Liu RM, Yuan Q | J Ethnopharmacol | 2026 | 0 |
| Novel insights into meningioma brain invasion with spatial transcriptomic profil [PMID:41486296] | Maier AD, Laurentiussen CO, Michaelsen S | Acta Neuropathol Commun | 2026 | 0 |
| Brain vascular stability relies on PAK2-cilia-PDGF-BB-HSPGs on basolateral side [PMID:41490797] | Prabhudesai S, Thirugnanam K, Song X, Ya | Life Sci Alliance | 2026 | 0 |
| Plasma platelet-derived growth factor receptor-β decrease correlates with blood- [PMID:41530860] | Li J, Li A, Ye C, Zhang L, Jiang M et al | Mol Neurodegener | 2026 | 0 |
| FOXF2 regulates pericyte-endothelial signaling required for vascular homeostasis [PMID:41680210] | Sun F, Zhao Y, Do J, Cheng P, Li E et al | Nat Commun | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.90 · 2026-04-06
closed · Rounds: 4 · Score: 0.83 · 2026-04-06
Hypotheses and analyses mentioning Are in their description or question text
Score: 0.670 · neurodegeneration · 2026-04-25
This hypothesis reconciles conflicting C1q phenotypes by placing receiver-cell state downstream of a common upstream C1q
Score: 0.661 · alzheimers · 2026-04-04
## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the
Score: 0.640 · neurodegeneration · 2026-04-28
Disrupted retrieval of cargo from endosomes to the trans-Golgi network (retromer dysfunction) impairs processing of APP,
Score: 0.626 · neurodegeneration · 2026-04-28
early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable pro
Score: 0.580 · neurodegeneration · 2026-04-24
A more mechanistic but less translationally mature possibility is that G2019S does not strongly alter total phospho-Rab
Score: 0.557 · neurodegeneration · 2026-04-02
## Mechanistic Overview Circadian-Gated Maresin Biosynthesis Amplification starts from the claim that modulating ALOX12
Score: 0.502 · als · 2026-04-26
CHI3L1 (YKL-40), CHIT1 (chitotriosidase), and CHI3L2 are among the most consistently elevated proteins in ALS biofluids
Score: 0.380 · late-onset-alzheimers · 2026-04-26
We hypothesize that rare loss-of-function variants in microglial-expressed genes within the TREM2-TYROBP signaling casca
Score: 0.380 · alzheimers · 2026-04-26
Despite different initial triggers (LPS, β-amyloid, aging), primed microglia may converge on a common 'epigenetic primin
Score: 0.345 · neurodegeneration · 2026-04-26
The same signal may be beneficial early and damaging late. Testing protective chromatin remodeling with single-cell meth
Score: 0.344 · neurodegeneration · 2026-04-26
The gap can be tested by treating age-linked CpG drift as an upstream driver rather than a passive correlate. If true, p
Score: 0.344 · neurodegeneration · 2026-04-26
The gap can be tested by treating age-linked CpG drift as an upstream driver rather than a passive correlate. If true, p
Score: 0.342 · neurodegeneration · 2026-04-26
A longitudinal biomarker panel centered on ATAC-seq accessibility can distinguish harmful mechanisms from protective ada
Score: 0.340 · molecular-biology · 2026-04-24
This is the weakest mechanistic proposal. It attempts to connect extracellular apoE particle quality to intracellular ER
Score: 0.327 · neurodegeneration · 2026-04-26
A longitudinal biomarker panel centered on ATAC-seq accessibility can distinguish harmful mechanisms from protective ada